

Screening of *FOXD3* targets in lung cancer via bioinformatics analysis

WENHUA JIANG¹, PENGFEI LIU²⁻⁶ and XIAODONG LI¹

¹Department of Radiotherapy, The Second Hospital of Tianjin Medical University, Tianjin 300211; ²Department of Lymphoma, ³National Clinical Research Center for Cancer, ⁴Key Laboratory of Cancer Prevention and Therapy, ⁵Tianjin's Clinical Research Center for Cancer, ⁶Sino-US Center of Lymphoma and Leukemia, Tianjin Medical University Cancer Institute and Hospital, Tianjin 300060, P.R. China

Received March 23, 2017; Accepted November 2, 2017

DOI: 10.3892/ol.2017.7685

Abstract. The purpose of the present study was to explore the targets of forkhead box D3 (*FOXD3*) in lung cancer, and thus contribute to the diagnosis and therapy of the disease. The gene expression profile of GSE64513 was downloaded from the Gene Expression Omnibus database. The dataset contained 3 *FOXD3* knockout A549 lung cancer cell samples and 3 normal A549 cell samples. The differentially expressed genes (DEGs) between the *FOXD3*-knockout and normal A549 cells were identified using the limma package in R. The alternative splicing genes (ASGs) in *FOXD3*-knockout samples were identified by Replicate Multivariate Analysis of Transcript Splicing software. The Database for Annotation, Visualization and Integrated Discovery was used to identify the enriched functions and pathways of DEGs and ASGs. A protein-protein interaction (PPI) network was constructed based on results from the Search Tool for the Retrieval of Interacting Genes database and visualized using Cytoscape software. A total of 1,853 DEGs and 2,249 ASGs were identified in *FOXD3*-knockout A549 cells compared with normal A549 cells. The DEGs were enriched in 338 Gene Ontology (GO) terms and 21 Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, and the ASGs were enriched in 470 GO terms and 22 KEGG pathways. A total of 199 overlaps between the DEGs and the ASGs were identified; a PPI network constructed based on the overlapping genes contained 97 nodes and 115 pairs. *FOXD3* may serve an important role in regulating the growth, migration and proliferation of tumor cells in lung cancer. The present study indicates that a number of genes, including *AURKA* and *NOS3*, may be targets of *FOXD3*, mediating its effect in lung cancer.

Introduction

Lung cancer is among the most common types of cancer, accounting for ~13% of all cancer cases (1). The generally poor prognosis of lung cancer renders it a leading cause of cancer-associated mortality worldwide (2). In 2010, 1.5 million mortalities due to lung cancer were reported, representing 19% of all cancer-associated mortality (3). The incidence of lung cancer has doubled in China over the past decade due to issues including the aging population, smoking and the reduced air quality (4). Lung cancer is initiated by the activation of oncogenes or the inactivation of tumor suppressor genes (5). Despite advances in diagnosis and treatment, the prognosis of lung cancer remains relatively poor. The identification of reliable biomarkers and novel genes involved in lung cancer carcinogenesis is important for improving the ability to predict the prognosis and to guide the therapy of lung cancer.

Forkhead box D3 (*FOXD3*) is a member of the FOX transcription factor family, which is characterized by a distinct forkhead domain (6). *FOXD3* acts as a transcriptional repressor or activator (7). The abnormal expression of *FOXD3* has been reported to participate in tumor onset and progression in non-small cell lung cancer tumor cells (8). Other studies have indicated tumor suppressive activities for *FOXD3*, including the inhibition of cell growth and invasion in various types of cancer, including gastric cancer and melanoma (9,10). A number of genes associated with tumorigenesis have been reported to be targets of *FOXD3*. One study demonstrated that *FOXD3* regulated *RND3* expression and migration properties in melanoma cells (11). Another reported that *FOXD3* exhibited tumor suppressive activity that affected the growth, aggressiveness and angiogenesis of neuroblastoma through the transcriptional regulation of *NDRG1* (12). However, the role of *FOXD3* in lung cancer remains uncharacterized.

In this study, differentially expressed genes (DEGs) and alternative splicing genes (ASGs) were identified in *FOXD3*-knockout samples compared with normal samples. Functional and pathway enrichment analyses of the DEGs and ASGs were performed. A protein-protein interaction (PPI) network was constructed based on the overlaps between the

Correspondence to: Dr Xiaodong Li, Department of Radiotherapy, The Second Hospital of Tianjin Medical University, 23 Pingjiang Road, Tianjin 300211, P.R. China
E-mail: xiaodonglitj@163.com

Key words: lung cancer, forkhead box D3, Gene Expression Omnibus database, bioinformatics

DEGs and ASGs. An improved understanding of *FOXD3* in regulating the process of lung cancer was obtained, which may allow the development of novel strategies for the diagnosis and therapy of lung cancer.

Materials and methods

Datasets. The gene expression profile GSE64513 was downloaded from the Gene Expression Omnibus (GEO; <http://www.ncbi.nlm.nih.gov/geo/>) database. The data set contained the RNAseq data from 6 samples, including 3 *FOXD3*-knockout A549 lung cancer cell samples and 3 normal A549 cell samples.

Screening of DEGs and ASGs. The data was first analyzed using FastQC (<http://www.bioinformatics.babraham.ac.uk/projects/fastqc>), a java-based high-throughput data quality control software. Reads with base quality scores <20 were discarded, and reads longer than 30 bp were selected for further investigation. The remaining reads were mapped to the GRCh37/hg19 genome based on the Tophat2 program (13). The number of reads mapped to the exons of each gene was counted with the HTSeq-Count tool (14) and regarded as the expression profile of each gene. Differently expressed genes (DEGs) in *FOXD3* knockout lung cancer samples compared with normal samples were identified using the edge R package (15) with the following thresholds: False discovery rate <0.01 and $|\log(\text{fold change})| > 1$. The hierarchical clustering of DEGs was performed using the heatmap.2 function of the gplots package in Various R Programming tool (version 2.12) (16). The alternative splicing genes (ASGs) in the *FOXD3* knockout samples were identified using the replicate multivariate analysis of transcript splicing (rMATS) program, a computer program designed to detect differential alternative splicing from replicate RNA-Seq data (17).

Functional and pathway enrichment analysis. The Database for Annotation, Visualization and Integrated Discovery (DAVID; <https://david.ncifcrf.gov/>) is a web-based tool for genomic functional annotations (18). To further explore the biological functions of the DEGs and ASGs, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed using DAVID, with the threshold of $P < 0.05$.

Construction of a PPI network. The overlapping DEGs and ASGs were analyzed using the Search Tool for the Retrieval of Interacting Genes (STRING; <http://string-db.org/>) (19,20). A PPI network to illustrate the identified interactions was constructed and visualized using Cytoscape 3.4 (21).

Results

Identification of DEGs and ASGs. The total number of reads, the number of mapped reads and the mapping rate of each sample is provided in Table I. A total of 1,853 DEGs were identified, of which 382 were upregulated and 1,471 were downregulated. The top 20 DEGs are listed in Table II. Fig. 1 demonstrates the hierarchical clustering results for each sample graphically (Fig. 1A), the fold-change trend of the expression

Table I. Total reads, the number of mapped reads, and the mapping rates of each sample.

Sample	Total reads	Mapped reads	Mapping rate, %
SRR1734826	10,339,232	9,252,784	89.5
SRR1734827	10,472,212	9,298,751	88.8
SRR1734828	10,868,010	9,651,798	88.8
SRR1734829	11,224,483	9,666,662	86.1
SRR1734830	10,548,877	9,241,415	87.6
SRR1734831	11,578,464	10,104,885	87.3

Table II. Top 20 differentially expressed genes of the forkhead Box D3-knockout lung cancer A549 cell samples compared with normal A549 cells.

Gene symbol	False discovery rate	P-value	Log fold change
<i>SAA1</i>	1.02×10^{-426}	8.46×10^{-313}	-7.70213
<i>C3</i>	3.82×10^{-478}	8.15×10^{-562}	-2.97374
<i>GAS6</i>	9.26×10^{-283}	2.01×10^{-286}	-2.52365
<i>CFB</i>	4.97×10^{-271}	1.44×10^{-274}	-3.25002
<i>LCN2</i>	7.38×10^{-254}	2.67×10^{-257}	-3.10027
<i>TGM2</i>	8.36×10^{-244}	3.63×10^{-247}	-2.45302
<i>SAT1</i>	3.53×10^{-238}	1.79×10^{-241}	-2.46616
<i>PDZK1IP1</i>	3.63×10^{-230}	2.11×10^{-233}	-4.94302
<i>PLAU</i>	7.60×10^{-226}	4.96×10^{-229}	-2.07647
<i>SAA2</i>	6.42×10^{-194}	4.65×10^{-197}	-7.47593
<i>TNIP1</i>	2.23×10^{-189}	1.78×10^{-192}	-2.05325
<i>SPP1</i>	2.23×10^{-189}	1.94×10^{-192}	2.29076
<i>SI00A8</i>	1.27×10^{-168}	1.20×10^{-171}	-3.79768
<i>TMEM132A</i>	1.42×10^{-166}	1.44×10^{-169}	-1.93297
<i>ASNS</i>	6.48×10^{-156}	7.04×10^{-159}	-2.09409
<i>SERPINE1</i>	2.92×10^{-149}	3.38×10^{-152}	-2.55607
<i>PHLDB2</i>	4.19×10^{-147}	5.17×10^{-150}	-1.54635
<i>ICAM1</i>	7.56×10^{-144}	9.87×10^{-147}	-2.03788
<i>CXCL8</i>	1.08×10^{-138}	1.48×10^{-141}	-5.25318

of the identified DEGs (Fig. 1B) and the hierarchical cluster analysis of the samples based on the DEGs (Fig. 1C). A total of 2,249 genes with alternative splicing were identified in *FOXD3*-knockout lung cancer samples compared with normal A549 cell samples, including 545 with an alternative 3' splice site, 412 with an alternative 5' splice site, 1,629 with mutually exclusive exons and 67 with retained introns.

Enriched GO terms and KEGG pathways of DEGs and ASGs.

The DEGs were enriched in 338 GO terms and 21 KEGG pathways. The ASGs were enriched in 470 GO terms and 22 KEGG pathways. The top 10 GO terms for the ASGs and DEGs are listed in Fig. 2A and B, respectively. Table III lists the enriched KEGG pathways for the ASGs and DEGs. The DEGs were predominately enriched in 'graft-vs.-host disease', 'hematopoietic cell lineage', 'ECM-receptor interaction' and




Figure 1. DEGs between 3 expression profiles from A549 cells with FOXD3 knockout and 3 from normal A549 cells. (A) Hierarchical clustering analysis of the 6 samples by MDS; (B) the fold change trend of the DEGs; and (C) the hierarchical clustering analysis of the samples based on the expression of the DEGs. DEGs, differentially expressed genes; FOXD3, forkhead box D3; MDS, multidimensional scaling; DEG, differentially expressed gene; FC, fold change.




Figure 2. The top 10 GO terms in which (A) the DEGs, and (B) the alternative splicing genes were enriched. GO, Gene Ontology; DEGs, differentially expressed genes.

‘NOD-like receptor signaling pathway’. The ASGs were predominately enriched in ‘ubiquitin mediated proteolysis’, ‘chronic myeloid leukemia’, ‘aminoacyl-tRNA biosynthesis’ and ‘mTOR signaling pathway’.

PPI network. A total of 199 overlaps between the DEGs and the ASGs were identified, and the PPI network constructed from the 199 overlapping genes contained 97 nodes and 115 pairs (Fig. 3). Table IV lists the top 20 pairs with highest

Table III. Enriched KEGG pathways for DEGs and ASGs between FOXD3-knockout and normal A549 cells.

A, Enriched KEGG pathways for DEGs		
Pathway name	Genes, n	P-value
Graft-vs.-host disease	12	0.0006
Hematopoietic cell lineage	18	0.0019
NOD-like receptor signaling pathway	14	0.0038
ECM-receptor interaction	17	0.0038
Cell adhesion molecules	23	0.0044
Allograft rejection	10	0.0045
Cytokine-cytokine receptor interaction	38	0.0055
Glycine, serine and threonine metabolism	9	0.0059
MAPK signaling pathway	38	0.0075
p53 signaling pathway	14	0.0085
Natural killer cell mediated cytotoxicity	22	0.0100
Toll-like receptor signaling pathway	18	0.0106
Viral myocarditis	14	0.0122
Nitrogen metabolism	7	0.0157
Arginine and proline metabolism	11	0.0217
Complement and coagulation cascades	13	0.0230
Pathways in cancer	42	0.0266
Axon guidance	20	0.0274
Pathogenic <i>Escherichia coli</i> infection	11	0.0344
B cell receptor signaling pathway	13	0.0413
Small cell lung cancer	14	0.0438

B, Enriched KEGG pathways for ASGs

Pathway name	Gene, n	P-value
Ubiquitin mediated proteolysis	33	0.0002
Chronic myeloid leukemia	20	0.0014
Aminoacyl-tRNA biosynthesis	13	0.0029
mTOR signaling pathway	15	0.0032
Renal cell carcinoma	18	0.0040
Pancreatic cancer	18	0.0054
Neurotrophin signaling pathway	26	0.0079
Pathways in cancer	55	0.0133
Ribosome	19	0.0173
Pyrimidine metabolism	20	0.0208
Acute myeloid leukemia	14	0.0215
Small cell lung cancer	18	0.0250
Wnt signaling pathway	28	0.0276
Cell cycle	24	0.0297
VEGF signaling pathway	16	0.0373
Lysine degradation	11	0.0377
Insulin signaling pathway	25	0.0387
Glioma	14	0.0403
Prostate cancer	18	0.0414
Lysosome	22	0.0465

Table III. Continued.

Pathway name	Genes, n	P-value
Endometrial cancer	12	0.0484
N-glycan biosynthesis	11	0.0495

KEGG, Kyoto Encyclopedia of Genes and Genomes; DEG, differentially expressed genes; ASG, alternative splicing gene; NOD, nucleotide oligomerization; ECM, extracellular matrix; MAPK, mitogen-activated protein kinase; mTOR, mechanistic target of rapamycin; tRNA, transfer RNA; VEGF, vascular endothelial proliferation factor.

combined scores, and Table V lists the top 10 nodes according to connectivity degree.

Discussion

Lung cancer is a serious threat to human health and survival (22). Despite progress in diagnosis and treatment, the 5-year survival rate of patients with lung cancer is only 9-20% (23). *FOXD3* has been suggested to be a tumor suppressor in various types of cancer (8-10). However, the underlying mechanism of *FOXD3* activity in lung cancer remains unclear. In the present study, DEGs and ASGs between *FOXD3*-knockout and normal lung cancer A549 cells were identified, and functional enrichment analysis was performed to identify the associated biological processes involved in lung cancer. Finally, a PPI network of the most significant genes was constructed. These results may contribute to the understanding of the role of *FOXD3* in lung cancer.

The most enriched GO terms for the DEGs were 'response to wounding', 'extracellular region', 'plasma membrane' and 'immune response'. The ASGs were mainly enriched in 'cytosol', 'intracellular organelle lumen', 'organelle lumen' and 'membrane-enclosed lumen' (Fig. 2). The wound response involves clotting and coagulation, tissue remodeling, cellular migration and proliferation, and angiogenesis (24). The majority of these processes also serve important roles in the progression of cancer. One study reported that the upregulation of factors associated with the 'wound response' term was highly prognostic of breast cancer survival, and revealed a strong association between the pathogenic conditions identified by this signature and those identified using serum-treated fibroblasts (25). In lung cancer, the upregulation of genes associated with the 'wound response' term has been demonstrated as predictive of poor overall survival time and increased risk of metastasis (26).

The cell membrane is a biological membrane that separates the interior of cells from the outside environment (27). Plasma membrane fluidity depends on the composition of the lipids and proteins in the membrane, and has been demonstrated to be significantly associated with the malignant potential of cancer cells (28), with alterations in the plasma membrane fluidity of cancer cells associated with their capacity to form metastases (29). In lung cancer, studies reported that patients with high plasma membrane fluidity had poorer prognoses than those with less fluid membranes,




Figure 3. PPI network demonstrating the interactions between overlapping DEGs and alternative splicing genes. PPI, protein-protein interaction; DEGs, differentially expressed genes.

Table IV. Top 20 pairs of the protein-protein interaction network as determined by the highest combined score.

Gene 1	Gene 2	Combined score
<i>SMC4</i>	<i>SMC2</i>	0.999
<i>NOP56</i>	<i>DKC1</i>	0.997
<i>TFRC</i>	<i>OPTN</i>	0.994
<i>SRM</i>	<i>ODC1</i>	0.989
<i>CDA</i>	<i>TYMP</i>	0.987
<i>HNRNPM</i>	<i>U2AF2</i>	0.979
<i>ZWILCH</i>	<i>CENPE</i>	0.977
<i>CEACAM6</i>	<i>CEACAM1</i>	0.970
<i>TGM2</i>	<i>FN1</i>	0.970
<i>NOS3</i>	<i>AKT3</i>	0.964
<i>DTYMK</i>	<i>NME1</i>	0.954
<i>CENPE</i>	<i>KIF18A</i>	0.946
<i>NOP56</i>	<i>NOC2L</i>	0.941
<i>ATG7</i>	<i>ULK1</i>	0.937
<i>ARHGAP11A</i>	<i>RAC2</i>	0.936
<i>ZWILCH</i>	<i>KIF18A</i>	0.930
<i>OASL</i>	<i>IRF1</i>	0.925
<i>HDAC9</i>	<i>PHF21A</i>	0.925
<i>HDAC9</i>	<i>NOS3</i>	0.923
<i>DKC1</i>	<i>NOC2L</i>	0.911

Table V. The top 10 nodes of the protein-protein interaction network as determined by the highest connectivity degree.

Gene	Degree
<i>AURKA</i>	11
<i>NOS3</i>	8
<i>NOC2L</i>	8
<i>CENPE</i>	7
<i>AKT3</i>	7
<i>NSUN2</i>	6
<i>SOD2</i>	5
<i>SMC4</i>	5
<i>RAC2</i>	5
<i>NOP56</i>	5

Cytosol is the fluid within cells, a component essential to the process of cytokinesis, a critical stage in cell proliferation (32,33). Another major function of cytosol is to transport metabolites; most tumor cells demonstrate different metabolic pathways to normal cells (34). One study indicated that metabolism contributed to the tumor proliferation, migration, and metastasis of lung cancer (35).

Other enriched GO terms, e.g., 'organelle lumen', have also been associated with tumorigenesis. Jingye *et al* (36) reported that a disordered pH in the organelle lumen is a common characteristic of cancer cells. Despite a number of studies reporting the *FOXD3*-mediated inhibition of the growth, invasion and

and the fluidity variable may be used as an independent additional prognostic factor (28,30,31).

migration of tumor cells in various types of cancer, including lung cancer (37-39), limited data is available regarding the association between *FOXD3* and these GO terms. As discussed, the identified GO terms have been associated with the growth, invasion and migration of tumor cells, thus it is speculated that *FOXD3* may affect the progression of lung cancer indirectly by regulating these biological processes.

From the identified KEGG pathways, the mechanistic target of rapamycin (mTOR) signaling pathway has also been associated with the growth and proliferation of tumor cells, and the deregulation of multiple elements of the mTOR pathway has been reported in numerous types of cancer (40). The NOD-like receptor signaling pathway is involved in the formation of inflammasomes, and numerous types of cancer are associated with inflamed tissue (41). However, the associations between *FOXD3* and the identified KEGG pathways require further exploration.

A total of 199 overlaps between the DEGs and the ASGs were identified, from which the PPI network was constructed (Fig. 3). The top 5 nodes of the PPI network, with the highest degree, were aurora kinase A (*AURKA*), nitric oxide synthase 3 (*NOS3*), NOD2-like nucleolar associated transcriptional repressor (*NOC2L*), centromere protein E (*CENPE*) and *AKT3*. The majority of these genes have been previously associated with tumorigenesis. *AURKA* and *NOS3* serve important roles in the development of various types of cancer, including lung cancer; *AURKA* is a cell cycle-regulated kinase involved in spindle formation and chromosome segregation (42). Various types of cancer exhibit the overexpression of *AURKA*, which is associated with chromosomal instability, centrosomal amplification/aneuploidy, therapeutic resistance, cell-cycle progression and anti-apoptosis. As an oncogene, *AURKA* is an important therapeutic target in lung cancer, and cell proliferation, apoptosis and cell cycle progression are associated with the expression of *AURKA* (43). *NOS3* encodes an enzyme that regulates the production of nitric oxide and contributes to uncontrollable cell growth in a number of cancer types (44). Various studies have demonstrated associations between *NOS3* and cancer processes. For example, Arıkan *et al* (45) reported that the *NOS3* Glu298Asp polymorphism may be associated with the risk and progression of colorectal cancer. Lee *et al* (46) reported that genetic polymorphisms in *NOS3* modified individual susceptibility to invasive breast cancer with lymph node involvement in Korean women. Furthermore, the expression of *NOS3* has been reported to contribute to the tumor angiogenesis and lymph metastasis of human non-small cell lung cancer (47).

The expression of other genes, including *CENPE*, *NOC2L* and *AKT3* has also been associated with tumorigenesis (48-50). *CENPE* was identified as a novel therapeutic candidate in neuroblastoma (50), and the selective activation of the *AKT3* protein promoted cell survival and tumor development in non-familial melanomas in one study (48). To the best of our knowledge, there is no experimental evidence of the direct association between *FOXD3* and these genes. However, the biological functions associated with these genes in the context of cancer correspond with the regulating mechanism of *FOXD3* in lung cancer. *FOXD3* acts as a tumor suppressor by regulating the expression of the target genes, thus inhibiting the growth, invasion and migration of tumor cells (51). Few specific targets for *FOXD3* in lung cancer have been reported,

whereas *AURKA* and *NOS3* serve critical roles in the growth, invasion and migration of tumor cells in lung cancer. Therefore, we speculate that *AURKA* and *NOS3* may be the targets of *FOXD3* that execute its effect in lung cancer. Confirmation of these conclusions and further exploration of the specific mechanism of *FOXD3* regulation in lung cancer are required.

In conclusion, *FOXD3* serves an important role in regulating the growth, migration and proliferation of lung cancer cells. Genes such as *AURKA* and *NOS3* may be targets of *FOXD3*, mediating its effect in lung cancer. The present study contributes to the existing understanding of the molecular mechanism of lung cancer and may provide data to contribute towards novel strategies for improving the diagnosis and therapy of lung cancer.

Acknowledgements

The present study was supported by the Municipal Science and Technology Commission of Tianjin (grant nos. 15ZLZLZF00440 and 16ZLZXZF00120) and the Health Bureau Science and Technology Foundation of Tianjin (grant no. 2014KZ102).

References

1. Reck M, Heigener DF, Mok T, Soria JC and Rabe KF: Management of non-small-cell lung cancer: Recent developments. *Lancet* 382: 709-719, 2013.
2. Grunnet M and Sorensen JB: Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. *Lung Cancer* 76: 138-143, 2012.
3. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, *et al*: Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of disease study 2010. *Lancet* 380: 2095-2128, 2012.
4. Wang Y, Chen J, Wu S, Hu C, Li X, Wang Y, Yang Y, Rajan N, Chen Y, Chen Y, *et al*: Clinical effectiveness and clinical toxicity associated with platinum-based doublets in the first-line setting for advanced non-squamous non-small cell lung cancer in Chinese patients: A retrospective cohort study. *BMC Cancer* 14: 940, 2014.
5. Cooper WA, Lam DC, O'Toole SA and Minna JD: Molecular biology of lung cancer. *Lung Cancer* 42: 378-386, 2004.
6. Weigel D and Jäckle H: The fork head domain: A novel DNA binding motif of eukaryotic transcription factors? *Cell* 63: 455-456, 1990.
7. Sutton J, Costa R, Klug M, Field L, Xu D, Largaespada DA, Fletcher CF, Jenkins NA, Copeland NG, Klemsz M and Hromas R: Genesis, a winged helix transcriptional repressor with expression restricted to embryonic stem cells. *J Biol Chem* 271: 23126-23133, 1996.
8. Yan JH, Zhao CL, Ding LB and Zhou X: FOXD3 suppresses tumor growth and angiogenesis in non-small cell lung cancer. *Biochem Biophys Res Commun* 466: 111-116, 2015.
9. Cheng AS, Li MS, Kang W, Cheng VY, Chou JL, Lau SS, Go MY, Lee CC, Ling TK, Ng EK, *et al*: *Helicobacter pylori* causes epigenetic dysregulation of FOXD3 to promote gastric carcinogenesis. *Gastroenterology* 144: 122-133.e9, 2013.
10. Abel EV and Aplin AE: FOXD3 is a mutant B-RAF-regulated inhibitor of G(1)-S progression in melanoma cells. *Cancer Res* 70: 2891-2900, 2010.
11. Katiyar P and Aplin AE: FOXD3 regulates migration properties and Rnd3 expression in melanoma cells. *Mol Cancer Res* 9: 545-552, 2011.
12. Li D, Mei H, Qi M, Yang D, Zhao X, Xiang X, Pu J, Huang K, Zheng L and Tong Q: FOXD3 is a novel tumor suppressor that affects growth, invasion, metastasis and angiogenesis of neuroblastoma. *Oncotarget* 4: 2021-2044, 2013.
13. Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R and Salzberg SL: TopHat2: Accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. *Genome Biol* 14: R36, 2013.

14. Anders S, Pyl PT and Huber W: HTSeq-a Python framework to work with high-throughput sequencing data. *Bioinformatics* 31: 166-169, 2015.
15. Culppepper SA and Aguinis HR: Is for Revolution: A Cutting-Edge, free, open source statistical package. *Organizational Res Methods* 13: 735-740, 2011.
16. Warnes GR, Bolker B, Bonebakker L, *et al*: Gplots: Various R programming tools for plotting data. R package version 2.12. 1. Available online at: <http://CRAN.R-project.org/package=gplots>.
17. Shen S, Park JW, Lu ZX, Lin L, Henry MD, Wu YN, Zhou Q and Xing Y: rMATS: Robust and flexible detection of differential alternative splicing from replicate RNA-Seq data. *Proc Natl Acad Sci USA* 111: E5593-E5601, 2014.
18. Dennis G Jr, Sherman BT, Hosack DA, Yang J, Gao W, Lane HC and Lempicki RA: DAVID: Database for Annotation, Visualization, and Integrated Discovery. *Genome Biol* 4: P3, 2003.
19. Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, Minguez P, Doerks T, Stark M, Muller J, Bork P, *et al*: The STRING database in 2011: Functional interaction networks of proteins, globally integrated and scored. *Nucleic Acids Res* 39 (Database issue): D561-D568, 2011.
20. Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, Lin J, Minguez P, Bork P, von Mering C and Jensen LJ: STRING v9.1: Protein-protein interaction networks, with increased coverage and integration. *Nucleic Acids Res* 41 (Database issue): D808-D815, 2013.
21. Smoot ME, Ono K, Ruscheinski J, Wang PL and Ideker T: Cytoscape 2.8: New features for data integration and network visualization. *Bioinformatics* 27: 431-432, 2011.
22. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. *CA Cancer J Clin* 61: 69-90, 2011.
23. Yang P: Epidemiology of lung cancer prognosis: Quantity and quality of life. *Methods Mol Biol* 471: 469-86, 2009.
24. Schäfer M and Werner S: Cancer as an overheating wound: An old hypothesis revisited. *Nat Rev Mol Cell Biol* 9: 628-638, 2008.
25. Troester MA, Lee MM, Carter M, Fan C, Cowan DW, Perez ER, Pirone JR, Perou CM, Jerry DJ and Schneider SS: Activation of host wound responses in breast cancer microenvironment. *Clin Cancer Res* 15: 7020-7028, 2009.
26. Chang HY, Nuyten DS, Sneddon JB, Hastie T, Tibshirani R, Sørlie T, Dai H, He YD, van't Veer LJ, Bartelink H, *et al*: Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. *Proc Natl Acad Sci USA* 102: 3738-3743, 2005.
27. Singleton P: Bacteria in Biology, Biotechnology, and Medicine. 5th edition, John Wiley, Hoboken, NJ, pp444-454, 1999.
28. Sok M, Sentjurs M, Schara M, Stare J and Rott T: Cell membrane fluidity and prognosis of lung cancer. *Ann Thorac Surg* 73: 1567-1571, 2002.
29. Nakazawa I and Iwaizumi M: A role of the cancer cell membrane fluidity in the cancer metastases: An ESR study. *Tohoku J Exp Med* 157: 193-198, 1989.
30. Deliconstantinos G: Physiological aspects of membrane lipid fluidity in malignancy. *Anticancer Res* 7: 1011-1021, 1987.
31. Nakazawa I and Iwaizumi M: A role of the cancer cell membrane fluidity in the cancer metastases: Aan ESR study. *Tohoku J Exp Med* 157: 193-198, 1989.
32. Winey M, Mamay CL, O'Toole ET, Mastronarde DN, Giddings TH Jr, McDonald KL and McIntosh JR: Three-dimensional ultrastructural analysis of the *Saccharomyces cerevisiae* mitotic spindle. *J Cell Biol* 129: 1601-1615, 1995.
33. Jana SS, Kawamoto S and Adelstein RS: A specific isoform of nonmuscle myosin II-C is required for cytokinesis in a tumor cell line. *J Biol Chem* 281: 24662-24670, 2006.
34. Weisiger RA: Cytosolic fatty acid binding proteins catalyze two distinct steps in intracellular transport of their ligands. *Mol Cell Biochem* 239: 35-43, 2002.
35. Li XB, Gu JD and Zhou QH: Review of aerobic glycolysis and its key enzymes-new targets for lung cancer therapy. *Thoracic Cancer* 6: 17-24, 2015.
36. Jingye Z, Zining L, Peng L, Jun Q, Xinwei L, Lu W, Wei F, Liang C, Xunbin W and Cong L: Selective imaging and cancer cell death via pH switchable near-infrared fluorescence and photothermal effects. *Chem Sci* 7: 5995-6005, 2016.
37. Ackermann S, Kocak H, Hero B, Ehemann V, Kahlert Y, Oberthuer A, Roels F, Theißen J, Odenthal M, Berthold F and Fischer M: FOXP1 inhibits cell growth and attenuates tumorigenicity of neuroblastoma. *Bmc Cancer* 14: 840, 2014.
38. Kos R, Reedy MV, Johnson RL and Erickson CA: The winged-helix transcription factor FoxD3 is important for establishing the neural crest lineage and repressing melanogenesis in avian embryos. *Development* 128: 1467-1479, 2001.
39. Wang C, Huang Y and Dai W: Tumor suppression function of FoxD3 in lung cancer. *Ir J Med Sci* 185: 547-553, 2016.
40. Pópulo H, Lopes JM and Soares P: The mTOR signalling pathway in human cancer. *Int J Mol Sci* 13: 1886-1918, 2012.
41. Castaño-Rodríguez N, Kaakoush NO, Goh KL, Fock KM and Mitchell HM: The NOD-like receptor signalling pathway in *Helicobacter pylori* infection and related gastric cancer: A case-control study and gene expression analyses. *PLoS One* 9: e98899, 2014.
42. Lens SM, Voest EE and Medema RH: Shared and separate functions of polo-like kinases and aurora kinases in cancer. *Nat Rev Cancer* 10: 825-841, 2010.
43. Ma ZL, Zhang BJ, Wang DT, Li X, Wei JL, Zhao BT, Jin Y, Li YL and Jin YX: Tanshinones suppress AURKA through up-regulation of miR-32 expression in non-small cell lung cancer. *Oncotarget* 6: 20111-20120, 2015.
44. Xu W, Charles IG, Moncada S, Gorman P, Sheer D, Liu L and Emson P: Mapping of the genes encoding human inducible and endothelial nitric oxide synthase (NOS2 and NOS3) to the pericentric region of chromosome 17 and to chromosome 7, respectively. *Genomics* 21: 419-422, 1994.
45. Arıkan S, Cacına C, Güler E, Çulcu S, Tuna G and Yaylımeraltan I: The effects of NOS3 Glu298Asp variant on colorectal cancer risk and progression in Turkish population. *Mol Biol Rep* 39: 3245-3249, 2012.
46. Lee KM, Choi JY, Lee JE, Noh DY, Ahn SH, Han W, Yoo KY, Hayes RB and Kang D: Genetic polymorphisms of NOS3 are associated with the risk of invasive breast cancer with lymph node involvement. *Breast Cancer Res Treat* 106: 433-438, 2007.
47. Wang JH, Chen LB, Heng-Hui MA and Meng K: Expressions of NOS2 and NOS3 in human non-small cell lung cancer and the relationship with tumor angiogenesis and lymph node metastasis. *J Med Postgraduates*, 2004.
48. Stahl JM, Sharma A, Cheung M, Zimmerman M, Cheng JQ, Bosenberg MW, Kester M, Sandirasegarane L and Robertson GP: Deregulated Akt3 activity promotes development of malignant melanoma. *Cancer Res* 64: 7002-7010, 2004.
49. Terasaka Y, Miyazaki D, Yakura K, Haruki T and Inoue Y: Induction of IL-6 in transcriptional networks in corneal epithelial cells after herpes simplex virus type 1 infection. *Invest Ophthalmol Vis Sci* 51: 2441-2449, 2010.
50. Balamuth NJ, Wood A, Wang Q, Jagannathan J, Mayes P, Zhang Z, Chen Z, Rappaport E, Courtright J, Pawel B, *et al*: Serial transcriptome analysis and cross-species integration identifies centromere-associated protein E as a novel neuroblastoma target. *Cancer Res* 70: 2749-2758, 2010.
51. Weiss MB, Abel EV, Dadpey N and Aplin AE: FOXD3 modulates migration through direct transcriptional repression of TWIST1 in melanoma. *Mol Cancer Res* 12: 1314-1323, 2014.